5GV Stock Overview
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Genovis AB (publ.) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.17 |
| 52 Week High | kr5.53 |
| 52 Week Low | kr2.17 |
| Beta | 1.44 |
| 1 Month Change | -23.36% |
| 3 Month Change | -50.85% |
| 1 Year Change | -57.55% |
| 3 Year Change | -53.09% |
| 5 Year Change | 34.47% |
| Change since IPO | 439.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5GV | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -8.6% | 2.4% | 1.2% |
| 1Y | -57.5% | -10.6% | 2.0% |
Return vs Industry: 5GV underperformed the German Life Sciences industry which returned -10.6% over the past year.
Return vs Market: 5GV underperformed the German Market which returned 2% over the past year.
Price Volatility
| 5GV volatility | |
|---|---|
| 5GV Average Weekly Movement | 9.2% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 5GV's share price has been volatile over the past 3 months.
Volatility Over Time: 5GV's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 37 | Fredrik Olsson | www.genovis.com |
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. The company provides FabALACTICA, a cysteine protease; FabRICATOR, a cysteine protease; and FabRICATOR Z, for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It offers FabULOUS (SpeB), a cysteine protease; GingisKHAN, a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease.
Genovis AB (publ.) Fundamentals Summary
| 5GV fundamental statistics | |
|---|---|
| Market cap | €159.47m |
| Earnings (TTM) | €5.26m |
| Revenue (TTM) | €13.60m |
30.3x
P/E Ratio11.7x
P/S RatioIs 5GV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5GV income statement (TTM) | |
|---|---|
| Revenue | kr159.07m |
| Cost of Revenue | kr15.16m |
| Gross Profit | kr143.91m |
| Other Expenses | kr82.41m |
| Earnings | kr61.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | 0.94 |
| Gross Margin | 90.47% |
| Net Profit Margin | 38.66% |
| Debt/Equity Ratio | 0% |
How did 5GV perform over the long term?
See historical performance and comparison